



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

CLADRIBINE

Generic	Brand	HICL	GCN	Exception/Other
CLADRIBINE	MAVENCLAD		44338	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

- Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS) (e.g., relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.) **AND** meet the following criterion?
 - The patient is 18 years of age or older

If yes, **approve for 48 weeks by GPID.**

APPROVAL TEXT: Renewal requires 1) physician attestation that the patient has demonstrated a clinical benefit compared to pre-treatment baseline, 2) the patient does not have lymphopenia, and 3) the patient has not received a total of two years of Mavenclad treatment (i.e., two treatment cycles divided into 2 yearly treatment courses).

If no, do not approve.

INITIAL DENIAL TEXT: The guideline named **CLADRIBINE (Mavenclad)** requires a diagnosis of a relapsing form of multiple sclerosis (MS) (e.g., relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.). In addition, the following criteria must be met:

- The patient is 18 years of age or older

RENEWAL CRITERIA

- Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS) (e.g. relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.)?

If yes, continue to #2.

If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

- Has the patient received a total of two years of Mavenclad treatment (i.e., two treatment cycles divided into 2 yearly treatment courses)?

If yes, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

If no, continue to #3.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

CLADRIBINE

RENEWAL CRITERIA (CONTINUED)

3. Does the patient meet **ALL** of the following criteria?

- Physician attestation that the patient has demonstrated a clinical benefit compared to pre-treatment baseline
- The patient does not have lymphopenia

If yes, **approve for 48 weeks by GPID.**

If no, do not approve.

RENEWAL DENIAL TEXT: The guideline named **CLADRIBINE (Mavenclad)** requires a diagnosis of relapsing forms of multiple sclerosis (MS) (e.g. relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.) AND the patient has not received a total of two years of Mavenclad treatment. In addition, the following criteria must be met:

- Physician attestation that the patient has demonstrated a clinical benefit compared to pre-treatment baseline
- The patient does not have lymphopenia

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Mavenclad.

REFERENCES

- Mavenclad [Prescribing Information]. Rockland, MA: EMD Serono, Inc., March 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/20

Created: 04/19

Client Approval: 11/19

P&T Approval: 10/19